n-CoDeR concept: Unique types of antibodies for diagnostic use and therapy

Expert Review of Molecular Diagnostics

Volumn 1, Issue 1, 2001, Pages 102-108

  Carlsson, Roland ^a   Söderlind, Eskil ^a  

^a BioInvent International AB   (Sweden)

Author keywords

Antibody engineering; Antibody library; CDR; scFv; Selection; Theraputic antibody

Indexed keywords

RECOMBINANT ANTIBODY;

ANTIBODY SPECIFICITY; ARTICLE; COMPUTER ANALYSIS; GENE LIBRARY; GENE SEQUENCE; GENETIC VARIABILITY; IMMUNOGENICITY;

EID: 0035558749     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.1.1.102     Document Type: Article

References (52)

1. Continuous cultures of fused cells secreting antibody of predefined specificity
2. Isolation of high affinity human antibodies directly from large synthetic repertoires
3. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library
4. Efficient construction of a large nonimmune phage antibody library: The production of high-affinity human single-chain antibodies to protein antigens
5. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies
6. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides
7. Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries
8. Antibody arrays for high-throughput screening of antibody-antigen interactions
9. Making antibody fragments using phage display libraries
10. Semisynthetic combinatorial antibody libraries: A chemical solution to the diversity problem
11. Selection and application of human single chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regions
12. Construction of a semisynthetic antibody library using trinucleotide oligos
13. Exploiting sequence space: Shuffling in vivo formed complementarity determining regions into a master framework
14. Antibody-antigen interactions: Contact analysis and binding site topography
15. Light-generated oligonucleotide arrays for rapid DNA sequence analysis
16. DNA chips: State-of-the art
17. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
18. 'Lymphochips' and cancer profiles
19. Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas
20. Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer
21. Linking gene expression patterns to therapeutic groups in breast cancer
22. Molecular portraits of human breast tumours
23. Antibodies in diagnostics - From immunoassays to protein chips
24. Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions
25. Initiation of Escherichia coli ribosomes on matrix coupled mRNAs studied by optical biosensor technique
26. Specific and nonspecific immunoassays to detect HAMA after administration of indium-111-labeled OV-TL 3 F(ab')2 monoclonal antibody to patients with ovarian cancer
27. Antibody response to murine anti-GD2 monoclonal antibodies: Correlation with patient survival
28. Will immunogenicity limit the use, efficacy and future development of therapeutic monoclonal antibodies?
29. Analysis of antiglobulin (HAMA) response in a group of patients with B-lymphocytic malignancies treated with 131I-Lym-1
30. Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size
31. Reshaping human antibodies for therapy
32. A humanized antibody that binds to the interleukin 2 receptor
33. Polymerase chain reaction facilitates the cloning, CDR-grafting and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins
34. Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface
35. Phage antibodies: Filamentous phage displaying antibody variable domains
36. Germ-line transmission and expression of a human-derived yeast artificial chromosome
37. Antigen-specific human antibodies from mice comprising four distinct generic modifications
38. Production of a diverse repertoire of human antibodies in genetically engineered mice
39. Diverting a protein from its cellular location by intracellular antibodies. The case of p21Ras
40. Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells and monocytes derived from CD34+ cells transduced with an intracellular antibody directed against human immunodeficiency virus Type 1 Tat
41. Clinical trials of antibody therapy
42. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma
43. Overview of the clinical development of rituximab: First monoclonal antibody approved for the treatment of lymphoma
44. Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: The Seattle experience
45. Phase I/II trial of multiple dose 131 Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma
46. A Phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma
47. Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells
48. Signaling antibodies in cancer therapy
49. Monoclonal antibody therapy of B cell lymphoma: Signaling activity on tumor cells appears more important than recruitment of effectors
50. Correlation between protein and mRNA abundance in yeast